Medios AG raises forecasts for financial year 2019 after particularly successful first quarter

  • Above-average sales and earnings growth in the first quarter of 2019
  • Group sales for full year to increase by up to 34 per cent to EUR 430 to 440 million
  • Management Board plans growth investments in subsidiary Medios Digital

Berlin, 23 April 2019 – Medios AG (‘Medios’), one of the leading Specialty Pharma companies in Germany, is raising its forecasts for the financial year 2019 after a particularly successful first quarter. According to IFRS, group sales for the period from January to March 2019 increased by 56 per cent year-on-year to EUR 107.0 million (previous year EUR 68.6 million). Group earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, rose by 38 per cent to EUR 3.6 million (previous year EUR 2.6 million). Group earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 33 per cent to EUR 3.2 million (previous year EUR 2.4 million). Thus, the key figures developed better than the Management Board had expected.

For the 2019 financial year, the Management Board therefore now expects group sales of EUR 430 to 440 million, adjusted EBITDA* of EUR 16.5 to 17.5 million and adjusted EBT* of EUR 14.5 to 15.5 million. This represents a sales growth of 31 and 34 per cent as well as a further increase in adjusted operating earnings*. Previously, the Management Board had expected group sales of EUR 400 to 410 million, adjusted EBITDA* of EUR 16 to 17 million, and adjusted EBT* of EUR 14 to 15 million.

As far as currently foreseeable, the guidance takes into account both the effects of the planned ‘Act for more Drug Safety’ on the business development of Medios as well as additional investments in the Drug Safety business unit and the establishment of the ‘Medios Apotheke’ brand. The new earnings forecasts also include additional investments in the digitalization, amongst others the significant increase in the headcount of the Medios Digital subsidiary.

Matthias Gärtner, CFO of Medios AG: ‘In the first three months of 2019, we surprisingly significantly increased the number of our partner pharmacies by a fifth from around 150 to roughly 180. This enabled us to increase sales and earnings even more strongly than in the already very strong prior-year quarter. We therefore remain very confident that we will continue the dynamic growth course of Medios Group in the current financial year and further improve profitability despite additional investments in digitalization.’

Manfred Schneider, CEO of Medios AG: ‘In the first quarter of 2019, we achieved two milestones with the positioning of our new brand ‘Medios Apotheke’ and the establishment of our new business unit Drug Safety. Together with the further expansion of our partner network, the extension of our product range and the specialization in additional indication areas, these milestones will contribute significantly to the growth of Medios Group.

The digitalization of the healthcare industry is developing rapidly. The introduction of the e-prescription will fundamentally change the entire pharmacy system in Germany. Therefore, we will invest more in our subsidiary Medios Digital in the coming months in order to position Medios AG as a leading Specialty Pharma company in the market with innovative concepts and to further strengthen our partner pharmacies.’

——————-

* EBITDA and EBT are each adjusted for extraordinary expenses for stock options of EUR 0.6 million (non-cash). EBT are also adjusted for extraordinary expenses for amortization of EUR 0.2 million (non-cash) on the customer base following the acquisition of operating units of BerlinApotheke Schneider & Oleski oHG.

About Medios AG

Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Contact

Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany

Tel.: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de

www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.